MedTrace Logo

Side Effects of a Single Shot Intrathecal Morphine in Clinical Practice, a Retrospective Analysis

NCT07238179 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2026-05-05

No results posted yet for this study

Summary

ITM has the potential to be a powerful tool for multimodal postoperative pain management, understanding, preventing and managing its side effects is crucial for upturn of patient safety and comfort. This retrospective audit will therefore be focused on the most reported side effects in daily clinical practice in patients having received ITM. The results of this study may lead to new insights into the clinically relevant risk-benefit balance of ITM and will contribute to the optimisation of its use in clinical practice.

Conditions

  • Morphine
  • Morphine Adverse Reaction
  • Morphine Induced Pruritis
  • Nausea and Vomiting, Postoperative
  • Analgesia
  • Spinal Analgesia

Interventions

DRUG

Intrathecal Morphine

The administration of intrathecal morphine (2µg/kg, with a maximum of 150-200µg) according to standard practice in a variety of surgical procedures. In addition, patients of 2 RCT using 4 or 5µg/kg (max 400 or 500µg), will also be included.

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Danny F Hoogma, MD, PhD · Universitaire Ziekenhuizen KU Leuven

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2025-12-31
Completion
2026-07-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07238179 on ClinicalTrials.gov